NCT00410605 2017-09-01
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
Genentech, Inc.
Hoffmann-La Roche
National Cancer Institute (NCI)